Does the media favor IDYA or PHAR?

In the previous week, Pharming Group had 5 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Pharming Group and 3 mentions for IDEAYA Biosciences. Pharming Group's average media sentiment score of 0.46 beat IDEAYA Biosciences' score of 0.38 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MBX or PHAR?

In the previous week, Pharming Group had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Pharming Group and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.52 beat Pharming Group's score of 0.46 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ALMS or PHAR?

Pharming Group has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 134.17 -$243.32M -$1.98 N/A Pharming Group $376.13M 2.21 $2.85M $0.12 97.67

Is ALMS or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to Alumis' net margin of -5,933.46%. Pharming Group's return on equity of 3.40% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -95.08% -75.81% Pharming Group 2.51% 3.40% 1.90%

Does the media favor ALMS or PHAR?

In the previous week, Alumis had 6 more articles in the media than Pharming Group. MarketBeat recorded 14 mentions for Alumis and 8 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.46 beat Alumis' score of 0.33 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IRON or PHAR?

In the previous week, Disc Medicine had 10 more articles in the media than Pharming Group. MarketBeat recorded 18 mentions for Disc Medicine and 8 mentions for Pharming Group. Disc Medicine's average media sentiment score of 0.56 beat Pharming Group's score of 0.46 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, QURE or PHAR?

Pharming Group has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 209.49 -$198.97M -$4.01 N/A Pharming Group $376.13M 2.21 $2.85M $0.12 97.67

Is QURE or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to uniQure's net margin of -1,350.73%. Pharming Group's return on equity of 3.40% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Pharming Group 2.51% 3.40% 1.90%

Does the media favor QURE or PHAR?

In the previous week, Pharming Group had 4 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for uniQure. uniQure's average media sentiment score of 1.13 beat Pharming Group's score of 0.46 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pharming Group (PHAR) Competitors

$11.72 -0.63 (-5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$11.74 +0.02 (+0.21%)

As of 07:34 PM Eastern

Compare

PHAR vs. IDYA, MBX, ALMS, IRON, and QURE

Should you buy Pharming Group stock or one of its competitors? Pharming Group's main competitors and comparable companies include IDEAYA Biosciences (IDYA), MBX Biosciences (MBX), Alumis (ALMS), Disc Medicine (IRON), and uniQure (QURE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharming Group compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Pharming Group has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.58	-$113.70M	-$1.94	N/A
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

Pharming Group has a net margin of 2.51% compared to IDEAYA Biosciences' net margin of -75.93%. Pharming Group's return on equity of 3.40% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Pharming Group	2.51%	3.40%	1.90%

IDEAYA Biosciences presently has a consensus target price of $50.13, indicating a potential upside of 38.09%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 229.92%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pharming Group had 5 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Pharming Group and 3 mentions for IDEAYA Biosciences. Pharming Group's average media sentiment score of 0.46 beat IDEAYA Biosciences' score of 0.38 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Summary

Pharming Group beats IDEAYA Biosciences on 11 of the 16 factors compared between the two stocks.

How does Pharming Group compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Pharming Group has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

In the previous week, Pharming Group had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Pharming Group and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.52 beat Pharming Group's score of 0.46 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

MBX Biosciences presently has a consensus target price of $75.63, suggesting a potential upside of 10.29%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 229.92%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

0.0% of Pharming Group shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pharming Group has a net margin of 2.51% compared to MBX Biosciences' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Alumis?

Alumis (NASDAQ:ALMS) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

0.0% of Pharming Group shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alumis currently has a consensus price target of $40.30, suggesting a potential upside of 59.23%. Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 229.92%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has a net margin of 2.51% compared to Alumis' net margin of -5,933.46%. Pharming Group's return on equity of 3.40% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-95.08%	-75.81%
Pharming Group	2.51%	3.40%	1.90%

Pharming Group has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	134.17	-$243.32M	-$1.98	N/A
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

Alumis has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

In the previous week, Alumis had 6 more articles in the media than Pharming Group. MarketBeat recorded 14 mentions for Alumis and 8 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.46 beat Alumis' score of 0.33 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pharming Group beats Alumis on 11 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Pharming Group has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharming Group has a net margin of 2.51% compared to Disc Medicine's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Pharming Group	2.51%	3.40%	1.90%

In the previous week, Disc Medicine had 10 more articles in the media than Pharming Group. MarketBeat recorded 18 mentions for Disc Medicine and 8 mentions for Pharming Group. Disc Medicine's average media sentiment score of 0.56 beat Pharming Group's score of 0.46 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Disc Medicine currently has a consensus target price of $106.00, suggesting a potential upside of 34.45%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 229.92%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Pharming Group compare to uniQure?

uniQure (NASDAQ:QURE) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Pharming Group has a net margin of 2.51% compared to uniQure's net margin of -1,350.73%. Pharming Group's return on equity of 3.40% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Pharming Group	2.51%	3.40%	1.90%

In the previous week, Pharming Group had 4 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for uniQure. uniQure's average media sentiment score of 1.13 beat Pharming Group's score of 0.46 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of uniQure shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	209.49	-$198.97M	-$4.01	N/A
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

uniQure currently has a consensus target price of $65.00, suggesting a potential upside of 33.69%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 229.92%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

uniQure has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Summary

Pharming Group beats uniQure on 9 of the 16 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$874.11M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	97.67	10.67	269.06	25.28
Price / Sales	2.21	1,294.08	602.43	91.76
Price / Cash	61.58	102.88	70.48	50.90
Price / Book	3.07	16.78	12.91	6.24
Net Income	$2.85M	-$13.32M	$3.45B	$347.60M
7 Day Performance	8.02%	1.74%	1.12%	1.07%
1 Month Performance	-12.60%	1.60%	1.79%	1.03%
1 Year Performance	2.99%	56.43%	67.69%	20.77%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	3.7447 of 5 stars	$11.72 -5.1%	$38.67 +229.9%	+9.8%	$874.11M	$376.13M	97.67	280	Short Interest Increase Gap Up
IDYA IDEAYA Biosciences	2.6093 of 5 stars	$37.08 +0.9%	$50.13 +35.2%	+50.2%	$3.24B	$218.71M	N/A	80
MBX MBX Biosciences	2.1984 of 5 stars	$66.26 +0.2%	$75.63 +14.1%	N/A	$3.19B	N/A	N/A	N/A
ALMS Alumis	3.6664 of 5 stars	$24.79 -10.0%	$40.30 +62.6%	+452.3%	$3.16B	$24.05M	N/A	N/A	Earnings Report Analyst Forecast Gap Down
IRON Disc Medicine	2.6151 of 5 stars	$81.27 +3.8%	$106.00 +30.4%	+30.9%	$3.12B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. IDYA, MBX, ALMS, IRON, and QURE

How does Pharming Group compare to IDEAYA Biosciences?

Summary

How does Pharming Group compare to MBX Biosciences?

Summary

How does Pharming Group compare to Alumis?

Summary

How does Pharming Group compare to Disc Medicine?

Summary

How does Pharming Group compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. IDYA, MBX, ALMS, IRON, and QURE

How does Pharming Group compare to IDEAYA Biosciences?

Which has higher valuation and earnings, IDYA or PHAR?

Is IDYA or PHAR more profitable?

Do analysts recommend IDYA or PHAR?

Do insiders & institutionals believe in IDYA or PHAR?

Does the media favor IDYA or PHAR?

Which has more risk & volatility, IDYA or PHAR?

Summary

How does Pharming Group compare to MBX Biosciences?

Which has stronger earnings & valuation, MBX or PHAR?

Does the media favor MBX or PHAR?

Which has more volatility and risk, MBX or PHAR?

Do analysts recommend MBX or PHAR?

Do insiders & institutionals hold more shares of MBX or PHAR?

Is MBX or PHAR more profitable?

Summary

How does Pharming Group compare to Alumis?

Do insiders and institutionals hold more shares of ALMS or PHAR?

Do analysts prefer ALMS or PHAR?

Is ALMS or PHAR more profitable?

Which has higher valuation & earnings, ALMS or PHAR?

Which has more volatility & risk, ALMS or PHAR?

Does the media favor ALMS or PHAR?

Summary

How does Pharming Group compare to Disc Medicine?

Which has preferable valuation and earnings, IRON or PHAR?

Do insiders & institutionals hold more shares of IRON or PHAR?

Is IRON or PHAR more profitable?

Does the media favor IRON or PHAR?

Which has more volatility & risk, IRON or PHAR?

Do analysts rate IRON or PHAR?

Summary

How does Pharming Group compare to uniQure?

Is QURE or PHAR more profitable?

Does the media favor QURE or PHAR?

Do insiders & institutionals hold more shares of QURE or PHAR?

Which has preferable valuation and earnings, QURE or PHAR?

Do analysts rate QURE or PHAR?

Which has more volatility & risk, QURE or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools